[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abramson Cancer Center at Penn Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":605},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,42,69,101,126,149,174,193,218,245,268,287,315,338,358,379,400,422,451,474,499,521,545,566,584],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053620","early-phase-1-picstat-pilot-study-for-cd8-petct-guided-lifileucel-treatment-in-advanced-melanoma-100053620",false,"NCT07700121","PICSTAT Pilot Study for CD8 PET\u002FCT-Guided Lifileucel Treatment in Advanced Melanoma","PICSTAT (PET Imaging of CD8 for Selection of Tumors for Autologous TIL): A Pilot Study Assessing the Use of CD8 PET\u002FCT (Zr-89 Crefmirlimab Berdoxam) to Enhance Lifileucel (AMTAGVI) Efficacy in Patients With Treatment Refractory Stage IV Melanoma","PICSTAT","Inclusion Criteria:\n\n* Must have a confirmed diagnosis of unresectable or metastatic melanoma (Stage IV)\n* Participants must have progressed following ≥ 1 prior systemic therapy for Stage IV or unresectable Stage III disease including a PD- 1 blocking antibody; and if BRAF V600 mutation-positive, a BRAF inhibitor or BRAF inhibitor in combination with MEK inhibitor.\n* At least two resectable previously non-irradiated lesions (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post- resection to generate TIL; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)\n* Lesions in the spleen should not be selected as resectable lesions, because they are not well evaluated by CD8 PET\u002FCT imaging due to high background signal in that organ\n* In addition to the two resectable lesions, at least one measurable target lesion, as defined by RECIST v1.1\n\n  1. Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatment was ≥ 3 months prior to Screening, and there has been demonstrated disease progression in that particular lesion\n  2. If a lesion is partially resected to generate TIL, and remains visible on the Baseline scan after surgery, then the partially resected lesion can be used for RECIST v1.1 response assessment, but only as a non- target lesion\n* Participants must be ≥ 18 years of age at the time of consent.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 .\n* Participants must have signed informed consent for the PICSTAT companion CD8 PET imaging protocol.\n* Participants are eligible for treatment with AMTAGVI per the recommendation of the treating oncologist.\n* Participant (or legally authorized representative) is capable of giving signed informed consent form (ICF) which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n* Participants of childbearing potential or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the protocol and practice an approved, highly effective method of birth control during treatment and for 12 months after receiving the last protocol-related therapy\n* Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to ≤ Grade 1 as per CTCAE v 6.0.\n\nExclusion Criteria:\n\n* Participants who have received an organ allograft or prior cell transfer therapy within the past 20 years that included a non-myeloablative or myeloablative chemotherapy regimen.\n* Participant has melanoma of uveal\u002Focular origin.\n* Participants who have a history of hypersensitivity to any component or excipient of lifileucel (AMTAGVI) or other study drugs: a. Hypersensitivity to PET tracer b. LD chemo regimen (cyclophosphamide, mesna, and fludarabine) c. Proleukin®, aldesleukin, IL-2 d. Antibiotics (ABX) of the aminoglycoside group (i.e., streptomycin, gentamicin); (These participants may be eligible if current hypersensitivity has been excluded.) e. Any component of the lifileucel infusion product formulation including dimethyl sulfoxide (DMSO), human serum albumin (HSA), IL-2, and dextran-40.\n* Participant has symptomatic untreated brain metastases. Participants with brain metastases may be considered for study participation with the following considerations and only after discussion with the Investigator:\n\n  1. Participants with asymptomatic brain metastases who do not clinically require treatment may be considered for study participation.\n  2. A participant with historically treated brain metastases (i.e., treatment was completed \\>28 days prior to consenting for study participation) may be considered for study participation if the participant is clinically stable for ≥ 2 weeks, there are no new or worsening brain lesions via screening CT or MRI, and the participant does not require ongoing corticosteroid treatment (\\>10 mg\u002Fday prednisone or equivalent).\n  3. If there are progressive or new brain metastases on the screening CT or MRI, the participant should first receive treatment for them prior to restarting or continuing screening. A participant with recently treated brain metastases (i.e., treatment of brain metastases was completed ≤ 28 days prior to consenting for study participation) may be considered for study participation if the participant is asymptomatic, clinically stable for ≥ 2 weeks, and does not require corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) by the end of the screening period. Repeat brain imaging is not required after treatment.\n* Participant requires systemic steroid therapy \\> 10 mg\u002Fday of prednisone or another steroid equivalent dose.\n\nParticipants receiving steroids as replacement therapy for adrenocortical insufficiency at ≤ 10 mg\u002Fday of prednisone or another steroid equivalent dose may be eligible\n\n* Participant has evidence of any active viral, bacterial, or fungal infection requiring ongoing systemic treatment or identified during screening\n* Participants who are pregnant or breastfeeding.\n* Participants who have active medical illness(es) that would pose increased risk for study participation, including: active uncontrolled infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.\n* Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of LD chemo regimen.","ALL","18 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This prospective, single-center pilot study is being performed to find out whether Zr-89 crefmirlimab berdoxam \"CD8 PET\u002FCT\" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel (\"Study Treatment\") in treating metastatic melanoma.\n\nParticipants must first provide consent to the companion protocol (UPCC 19426, PICSTAT CD8 PET) before being eligible to consent to this protocol.",[28],"Unresectable or Metastatic Melanoma","NOT_YET_RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-10-01",{"date":37,"type":22},"2029-10-01",{"name":39,"class":40},"Abramson Cancer Center at Penn Medicine","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100639699","phase-1-combining-neo-adjuvant-atr-inhibition-with-nodal-sbrt-for-early-stage-resectable-hpv-opsccs-100639699","NCT07578467","Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs","A Phase Ib\u002FII Study Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs","Inclusion Criteria:\n\n* Age ≥ 18\n* Patients that have been diagnosed with HPV-positive throat cancer (OPSCC) at an early stage (stage I or II), confirmed by a biopsy.\n* Patients' blood calcium level is within a safe range\n* Patients' blood, kidney, and liver health are strong enough, shown through specific medical test results\n* If a participant is female, she must not be pregnant or breastfeeding.\n* If a participant is male, he must agree to use highly effective birth control from the start of the study until a short period after the last dose of the study drug.\n\nExclusion Criteria:\n\n* Patients with late-stage tumors (Stage III or IV)\n* If the cancer has already spread to distant parts of the body (M1) when first diagnosed\n* Prior advanced head and neck cancer requiring radiation or major surgery\n* Patients whose original tumor site cannot be identified\n* Patients that have a known additional malignancy that is progressing or requires active treatment\n* Patients that had a surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119. This does not include procedures that are used to diagnose or determine extent of study disease (such as biopsies).\n* Patients taking medications that strongly affect how the body processes certain drugs (CYP enzymes) at the same time as the study treatment.\n* Patients with active infections and\u002For receiving systemic antibiotics or anti-viral medications.\n* Patients with uncontrolled HIV or active hepatitis B or C are usually not eligible. However, those whose infections are well-controlled on treatment for at least a month and meet certain viral load limits can participate\n* Current or past diagnosis of leukemia within the past 5 years.\n* Patients with a history of non-malignant gastrointestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.\n* Patient has uncontrolled hypertension at time of enrollment.\n* Patients who recently had serious kidney problems or kidney disease.\n* Patients cannot have taken another experimental drug within 30 days-or within a period equal to five times that drug's half-life-before starting this study\n* Medical illness that, in the opinion of the Investigator, may impact the safety of the patient\n* Patients who use recreational drugs or have mental health conditions that might make it hard to follow study visits, based on the doctor's judgment.\n* Known hypersensitivity to ATRN-119 or its ingredients\n* Patients with serious liver disease or liver problems that could affect how the body processes the study drug\n* Patients who are fairly limited in daily activities (ECOG score of 2 or higher)\n* Patients with serious other health problems that the doctor thinks could prevent them from completing the study\n* Pregnancy or lactation\n* Inability to provide informed consent",{"count":50,"type":22},35,[52,53],"PHASE1","PHASE2","This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat early-stage throat cancer that is caused by HPV.\n\nThe goal of this study is to treat cancer effectively while reducing side effects and helping patients maintain a better quality of life over the long term. Researchers hope that this approach will be just as successful-or possibly more successful-than current treatments, which already have high cure rates.\n\nParticipants will:\n\n* Take 800mg of ATRN-119 every day for 10 days\n* Receive 1 treatment (called a \"fraction\") of SBRT to the neck on day 3 of ATRN-119 dosing.\n* Keep a short diary to track ATRN-119 dosing. The diary will be provided by study team\n* Receive standard of care treatment after treatment with ATRN-119 + SBRT including TransOral Robotic Surgery (TORS) to remove the primary tumor with Neck Dissection and adjuvant therapy (if indicated)\n* Receive additional safety checkups and tests by researchers during routine visits with their cancer doctor for 2 years after study treatment",[56,57,58,59,60],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma","HPV (Human Papillomavirus)-Associated Carcinoma","HPV Associated Cancers","Oropharyngeal HPV Squamous Cell Carcinoma","2026-06-30",{"date":63,"type":33},"2026-07-02",{"date":65,"type":22},"2026-05-31",{"date":67,"type":22},"2030-05-31",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100629759","phase-1-radiation-oral-vancomycin-and-car-t-for-b-cell-lymphomas-100629759","NCT07478848","Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy","Inclusion Criteria:\n\n* Male or female subject aged ≥ 18 years.\n* Pathologically confirmed B-cell lymphoma patients intended for standard of care CAR-T\n* ECOG Performance Status ≤ 2.\n* Subjects must be clinically eligible to receive standard of care anti-CD19 CAR-T\n* Subjects must have at least one site of disease amenable to radiation, with the ability to deliver radiation to at least 50% of involved sites\n* Subjects must have at least one site of measurable disease based on CT or FDG PET\n* Subjects must not be anticipated to require additional therapy beyond bridging radiation listed in this protocol for control of their lymphoma\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause.\n\nThe following age-specific requirements apply:\n\nWomen \\\u003C 50 years of age: amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n\nWomen ≥ 50 years of age: amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or had radiation-induced menopause with last menses \\>1 year ago; or had chemotherapy-induced menopause with last menses \\>1 year ago; or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Unable to take oral vancomycin for any reason, including: Allergy or Inability to swallow drug\n* Known history of vancomycin resistant enterococcus (VRE)\n* Contraindications to radiation therapy, including scleroderma, systemic lupus erythematosus, Crohn disease, ulcerative colitis, or idiopathic pulmonary fibrosis\n* History of radiation pneumonitis or other grade 4 radiation-related adverse event\n* Prior or concurrent malignancy whose natural history or treatment which has the potential to interfere with the safety or efficacy assessment of the radiation therapy are eligible for this trial.\n* Severe, uncontrolled, significant intercurrent or recent illness that would exclude them from being a candidate for standard-of-care CART therapy.\n* Known uncontrolled HIV infection with a detectable viral load at the time of screening. Note: Patients on effective antiretroviral therapy or who will plan on going on antiretroviral therapy at the time of screening are eligible for this trial. HIV testing is not required for eligibility.\n* Active infection that required the use of antibiotics within 4 weeks prior to registration\n* Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures",{"count":77,"type":22},14,[52],"This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas",[81,82,83,84,85],"Large B Cell Lymphoma","Non Hodgkin Lymphoma (NHL)","Diffuse Large B Cell Lymphoma (DLBCL)","Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed",[87,88,89,90,91],"non-hodgkin lymphoma","NHL","large B cell lymphoma","DLBCL","diffuse large B cell lymphoma","RECRUITING","2026-06-29",{"date":95,"type":33},"2026-07-01",{"date":97,"type":33},"2026-05-29",{"date":99,"type":22},"2029-01-01",{"name":39,"class":40},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":108,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100457909","ftt-petct-in-metastatic-prostate-cancer-100457909","NCT05242744","FTT PET\u002FCT in Metastatic Prostate Cancer","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET\u002FCT) in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n1. Participants will be ≥ 18 years of age\n2. Histologically proven prostate carcinoma\n3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET\u002FCT, Ultrasound)\n4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and\u002For androgen deprivation therapy (ADT) and\u002For chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.\n5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n2. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study","MALE",{"count":110,"type":22},30,"OBSERVATIONAL","Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET\u002FCT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.",[114],"Prostate Cancer Metastatic",[116,117],"PET\u002FCT","PARP inhibitor","2026-06-24",{"date":120,"type":33},"2026-06-26",{"date":122,"type":33},"2023-03-01",{"date":124,"type":22},"2027-07",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":134,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":41},"100641461","a-mixed-methods-metabolomics-investigation-of-lifestyle-and-energy-balance-during-breast-cancer-survivorship-100641461","NCT07655934","A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship","The MILES Study: A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship","MILES","Inclusion Criteria:\n\n* Adult women (age 18 years or older)\n* Able to read English or Spanish\n* Newly diagnosed with primary stage 0, I, II, or III breast cancer\n* Pathological diagnosis within the previous 60 days\n* Scheduled to have surgery with a Penn Medicine surgeon\n\nExclusion Criteria:\n\n* Women age less than 18 years\n* Women without a new primary breast cancer diagnosis\n* Women who are pregnant","FEMALE",{"count":136,"type":22},100,[138],"NA","The MILES Study is a longitudinal, mixed-methods investigation of urinary biomarkers, energy balance, and lifestyle modifications in diverse women during early breast cancer treatment. The study's overarching goal is to assess dietary quality and physical activity changes over time using reliable, scalable tools suitable for clinical or population settings, supporting newly diagnosed patients in adopting and maintaining healthy behaviors through treatment and survivorship.",[141],"Breast Cancer","2026-06-22",{"date":118,"type":33},{"date":145,"type":33},"2026-01-20",{"date":147,"type":22},"2028-12",{"name":39,"class":40},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100580452","photobiomodulation-in-head-and-neck-cancer-related-chronic-lymphedema-100580452","NCT06837480","Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema","Placebo-Controlled Phase II Randomized Clinical Trial of Photobiomodulation Therapy in Head and Neck Cancer Survivors With Chronic Lymphedema","Inclusion Criteria:\n\n\\>18 years of age Biopsy proven head and neck cancer No evidence of cancer at the time of study enrollment, between 12- and 60-month post-cancer treatment Chronic lymphedema (defined as lymphedema persisting for a minimum of 6 months) A minimum of 2 sites of external lymphedema At least 1 site with lymphedema of moderate severity as assessed using the HN-LEF Assessment Criteria Failed lymphedema therapy (defined as any of the following: incomplete response to therapy, progression of lymphedema after therapy, inability to perform effective self-care resulting in fluid re-accumulation; and inability to complete treatment due to systems barriers). In addition, patients must be able to understand English in order to complete questionnaires; and to provide informed consent.\n\nExclusion Criteria:\n\nPatients will be excluded if they have any of the following medical conditions that would prohibit the safe implementation of PBMT:\n\nWomen of childbearing age and potential Acute cellulitis within the soft tissues in the head and neck region Chronic inflammatory diseases Venous thrombosis Carotid artery stenosis Requiring ongoing use of diuretics and corticosteroids Pre-existing skin rash, ulceration, open wound in the treatment area Active lymphedema or physical therapy (including hyperbaric oxygen or trental) Allergic and other systemic skin diseases",{"count":157,"type":22},150,[138],"The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.",[161,162],"Head and Neck Cancer","Lymphedema of the Head and Neck",[164],"Head and neck cancer, chronic lymphedema, photobiomodulation","2026-06-19",{"date":167,"type":33},"2026-06-23",{"date":169,"type":33},"2026-01-15",{"date":171,"type":22},"2029-11-30",{"name":39,"class":40},2,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100575328","consolidative-metastasis-and-primary-directed-therapy-mpdt-for-renal-cell-carcinoma-rcc-100575328","NCT06770855","Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)","A Phase II Study of Total Consolidative Metastasis-and-primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC).","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma (mixed histology acceptable but must have clear cell component)\n* Metastatic clear cell RCC with 5 or fewer metastases at enrollment (excluding pulmonary nodules \\\u003C1.0cm)\n* Stable disease or partial response as assessed by investigators following at least 6 months of immune checkpoint blockade-based therapy.\n* Has disease amenable for total consolidative focal therapy (this will be determined by a multidisciplinary team which may include a combination of medical oncologists, urologists, interventional radiologists, and radiation oncologists).\n* ECOG performance status \\\u003C 2\n* Must have archival tissue (slide or Formalin-Fixed Paraffin-Embedded tissue) preceding prior systemic treatment for comparison to tissue from consolidation\n* Consolidation surgery and biopsies are strongly encouraged to be within 42 days +\u002F- 7 days of holding systemic therapy.\n\nExclusion Criteria:\n\n* Subjects who have progressed during the first 6 months of immune checkpoint-blockade based therapy as determined by study investigator.\n* Subjects who have a need for urgent focally directed therapy (i.e. symptomatic brain or spinal metastases). Stable spinal metastases resected and\u002For treated with SBRT in advance of or concurrently with immune checkpoint-blockade based therapy are allowed to participate.\n* Any female of child-bearing potential who has a positive urine pregnancy test within 72 hours before screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Participants must be excluded\u002Fdiscontinued from the trial in the event of a positive or borderline positive serum pregnancy test result.",{"count":182,"type":22},23,[138],"This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response\u002Fstable disease after at least 6 months of immune checkpoint blockade-based therapy for metastatic clear cell RCC. The investigators hypothesize that patients who undergo total consolidative MPDT followed by systemic therapy discontinuation will have a 12-month treatment-free survival rate of 32% compared to a null hypothesis of 13%",[186],"Renal Cell Carcinoma","2026-06-18",{"date":167,"type":33},{"date":61,"type":22},{"date":191,"type":22},"2028-09",{"name":39,"class":40},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100641743","early-phase-1-pilot-study-of-tumorglow-for-intraoperative-molecular-imaging-of-sarcoma-metastases-to-the-lungs-in-pediatric-patients-100641743","NCT07658768","Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients","TumorGlow","Inclusion Criteria:\n\n* 1\\. Male and female children (12 - 17 years of age) with a primary diagnosis, or a high clinical suspicion of a solid tumor with metastasis to the lung warranting surgery based on CT\u002FPET or other imaging 2. Are scheduled to undergo surgical resection for suspected metastasis 3. Female subjects of childbearing potential (including those less than 2 years postmenopausal) agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after infusion of ICG. Male subjects who are are sexually active (and capable of producing sperm) with a partner that could become pregnant, must agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after infusion of ICG.\n\nExclusion Criteria:\n\n* 1\\. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject 2. History of anaphylactic reactions to ICG. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation 3. A positive serum pregnancy test at screening for female subjects of childbearing potential. Note that subjects with a positive pregnancy test on the day of infusion will be discontinued from study and will not receive the study drug.\n\n  4\\. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol and follow-up schedule 5. Impaired liver function defined as values \\> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT),aspartate aminotransferase (AST), or alkaline phosphatase (ALP), or \\>2x ULN for total bilirubin except in subjects with Gilbert's syndrome. \\*For subjects with Gilbert's syndrome, total bilirubin levels exceeding 3 mg\u002FdL will be excluded.\\* 6. Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to the administration of study drug 7. History of uncontrolled hypertension. (e.g., history of an emergency room \\[ER\\] admission for hypertensive crisis or ≥ 3 BP medications) 8. Known sensitivity to fluorescent light","12 Years","17 Years",{"count":203,"type":22},20,[25],"Subjects will undergo infusion of 5 mg\u002Fkg indocyanine green, ICG (\"TumorGlow\") intravenously up to 5-days prior to surgery. Then, during the surgical procedure the next day, the subjects will undergo standard-of-care surgery. During the surgery, the fluorescence from the tumor will be used to localize lesions and ensure the entire tumor has been removed, as well as locate any un-expected tumors. The goal of this protocol is to evaluate safety and collect initial efficacy data using indocyanine green with NIR fluorescence imaging in a pediatric patient population undergoing pulmonary metastatectomy.",[207],"Sarcoma Metastatic",[209,210],"metastasis","sarcoma","2026-06-17",{"date":142,"type":33},{"date":214,"type":22},"2026-09-01",{"date":216,"type":22},"2027-05-01",{"name":39,"class":40},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":41},"100603173","phase-4-allergy-delabeling-in-antibiotic-stewardship---intervention-100603173","NCT07133074","Allergy Delabeling in Antibiotic Stewardship - Intervention","Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention","RENEW-IN","Inclusion Criteria:\n\n* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service\n* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and\u002For carbapenem)\n\nExclusion Criteria:\n\n* patients with a history of severe cutaneous adverse reaction\n* patients with a history of Stevens-Johnson syndrome\n* patients with a history of toxic epidermal necrolysis\n* patients with a history of drug-induced exfoliative dermatitis\n* patients with a history of drug reaction with eosinophilia and systemic symptoms\n* patients with a history of acute generalized exanthematous pustulosis",{"count":227,"type":22},3800,[229],"PHASE4","The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.",[232,233],"Beta Lactam Allergy","Hematologic Malignancy",[235,236,237],"penicillin allergy","hematologic cancer","allergy delabeling","2026-06-15",{"date":211,"type":33},{"date":241,"type":33},"2026-04-20",{"date":243,"type":22},"2029-11",{"name":39,"class":40},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":41},"100495097","qol-and-sarcopenia-in-patients-with-ascites-100495097","NCT05726747","QOL and Sarcopenia in Patients With Ascites","Health-related Quality of Life Outcomes and Changes in Sarcopenia in Patients With Refractory Ascites","Inclusion Criteria:\n\n1. Age \\>\u002F=18\n2. Eastern Cooperative Oncology Group (ECOG) performance score \\\u003C 3\n3. Refractory ascites due to cirrhosis or malignancy, requiring more than 1 therapeutic paracentesis in a 6 week period within 3 months of enrollment.\n4. Capable of giving informed consent\n\nExclusion Criteria:\n\n1. Life expectancy less than 3 months\n2. Unable to participate in neuropsychological tests\u002Fquestionnaires\n3. Pregnant or nursing women. .",{"count":253,"type":22},70,"Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of life survey instruments specific to benign and malignant etiologies.\n\nSarcopenia is a condition that is prevalent in cancer and cirrhosis. Current data is retrospective and associative, evaluating heterogeneous patient populations at different stages within the timeline of refractory ascites. The other primary objective of this study is to study sarcopenia in a prospective fashion and to understand its kinetics once a patient develops refractory ascites.\n\nProspectively-obtained measures of deterioration in patient-reported outcomes and in muscle mass will form the basis for the next stage of investigation of interventions to mitigate these declines.",[256,257],"Ascites Hepatic","Ascites, Malignant",[259,260],"ascites","sarcopenia","2026-06-12",{"date":238,"type":33},{"date":264,"type":33},"2023-05-23",{"date":266,"type":22},"2027-10",{"name":39,"class":40},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":134,"minAge":19,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":41},"100627889","engaging-m-health-for-symptom-monitoring-and-health-promotion-for-women-on-endocrine-therapy-for-breast-cancer-emshape-100627889","NCT07454499","Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)","Inclusion Criteria:\n\n* Participants must identify as a woman\n* Participants must be age 18 or older\n* Participants must have a diagnosis of Stage 0, I, II, or III HR+ breast cancer\n* Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole) within 16 weeks of study registration.\n* Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization.\n* Participants who received chemotherapy must have finished it at least 14 days prior to randomization.\n* Speak and read in English\n* Own an internet-enabled cell phone\n* Capable of using the electronic pill bottle\n* Concomitant radiotherapy is allowed. Concomitant maintenance targeted or biologic therapy (e.g., anti-HER2 therapy, osteoclast inhibitor therapy, CDK 4\u002F6 inhibitor, ovarian function suppression medications) is allowed.\n\nExclusion Criteria:\n\n* Metastatic (Stage IV) breast cancer\n* Male gender\n* Prior treatment with endocrine therapy for breast cancer\n* Communication difficulties such as: Uncorrected or uncompensated hearing and\u002For vision impairment, uncorrected or uncompensated speech defects, uncontrolled psychiatric\u002Fmental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks",{"count":275,"type":22},60,[138],"The purpose of the study is to learn more about ways to help patients understand and manage side-effects from hormone therapy. The investigators will use the information from this study to design future studies to better understand how our well our tools work to help patients monitor and manage symptoms from hormone therapy and to stay on their hormone therapy for the recommended period of time.",[279],"Cancer","2026-06-10",{"date":261,"type":33},{"date":283,"type":33},"2026-05-13",{"date":285,"type":22},"2027-12-31",{"name":39,"class":40},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":293,"sex":18,"minAge":294,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":303,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":41},"100608281","catalyzing-cigarette-smoking-cessation-through-harm-reduction-sampling-among-people-unmotivated-to-quit-100608281","NCT07199517","Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e., speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. Have a carbon monoxide (CO) greater than or equal to 10 ppm\n4. Not using any forms of nicotine regularly other than cigarettes.\n5. Not interested in quitting smoking in the next 30 days.\n6. Capable of giving written informed consent, including compliance with the requirements and restrictions listed in the combined consent and HIPAA form\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, IQOS, ONPS, etc.).\n2. Current or impending (during the study period) enrollment or plans to enroll in a smoking cessation program.\n3. Current use of smoking cessation medication.\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, uncontrolled hypertension, cardiovascular event).\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",true,"21 Years",{"count":296,"type":22},472,[138],"This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of two harm-reduction products (ECIG, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior.",[300,301,302],"Cigarette Smoking","Tobacco Use","Cigarette Smoking Behavior",[304,305,306,307],"cigarette smoking","harm reduction","sampling","nicotine replacement",{"date":309,"type":33},"2026-06-11",{"date":311,"type":33},"2026-01-12",{"date":313,"type":22},"2030-07-31",{"name":39,"class":40},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":134,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":337},"100497549","phase-2-proton-therapy-for-post-surgical-treatment-of-gynecologic-cancer-100497549","NCT05758688","PROton Therapy for Post Surgical Treatment of GYNecologic Cancer","Adjuvant Proton Whole Pelvis Radiation Therapy for Treatment of Post-Surgical Gynecologic Cancers","PROPS GYN","Inclusion Criteria:\n\n* Histologically confirmed cervical or endometrial cancer\n* Indication for adjuvant whole pelvic radiation therapy, with or without systemic therapy\n* Age of 18 years or older\n* Written informed consent\n* ECOG of 0-2 within 3 months of enrolling\n\nExclusion Criteria:\n\n* Prior course of pelvic radiation\n* Metastatic disease outside of the pelvis\n* Active inflammatory bowel disease\n* Incapacity to provide informed consent",{"count":7,"type":22},[53],"This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.",[327,328,329],"Cervical Cancer","Uterine Cancer","Endometrial Cancer","2026-06-09",{"date":280,"type":33},{"date":333,"type":33},"2023-11-06",{"date":335,"type":22},"2026-12",{"name":39,"class":40},3,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":41},"100388022","phase-2-carboplatin-taxane-and-ramucirumab-for-patients-with-nsclc-after-pemetrexed-or-pembrolizumab-maintenance-100388022","NCT04332367","Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And\u002FOr Pembrolizumab","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to 4-6 cycles of Pem\u002FCarbo\u002FPembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.\n* PS 0-1\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* Other active invasive malignancy requiring ongoing therapy\n* Grade 2 or higher sensory neuropathy\n* Evidence of untreated brain metastases\n* History of bleeding diatheses or recent, antecedent hemoptysis (\\> 1\u002F2 teaspoon in prior 2 months)",{"count":346,"type":22},59,[53],"The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.",[350],"Non-small Cell Lung Cancer","2026-06-08",{"date":280,"type":33},{"date":354,"type":33},"2020-08-01",{"date":356,"type":22},"2026-09-30",{"name":39,"class":40},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":134,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":41},"100509651","phase-2-18ffes-petct-in-uterine-cancer-100509651","NCT05916196","[18F]FES PET\u002F.CT in Uterine Cancer","[18F]FLUOROESTRADIOL (FES) PET\u002FCT IMAGING OF THE ESTROGEN RECEPTOR IN PATIENTS WITH METASTATIC OR RECURRENT UTERINE CANCER","Inclusion Criteria\n\n1. Participants will be ≥ 18 years of age\n2. Recurrent or metastatic or intact non-operated uterine cancer not treated with surgery that is biopsy-proven or demonstrated on other standard of care imaging (e.g. CT, FDG PET\u002FCT, MRI, bone scan, x-ray, ultrasound)\n3. At least one lesion outside the liver detected by standard of care imaging (e.g.CT, FDG PET\u002FCT, MRI, bone scan, x-ray, ultrasound)\n4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n5. Subjects that are currently on or have recently discontinued tamoxifen or fulvestrant would require an 8-week or 28-week, respectively, washout period prior to FES PET\u002FCT scan.\n\nExclusion Criteria\n\n1. Females who report they are pregnant at screening will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential prior to FES injection.\n2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study",{"count":110,"type":22},[53],"Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.\n\n\\[18F\\]fluoroestradiol (FES) PET\u002FCT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET\u002FCT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET\u002FCT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy). The selection of therapy will be made by a treating physician and will not be affected by participation in this imaging study. Results of the FES PET\u002FCT scan may be shared with the treating physician or subject by request but will not be used to make clinical decisions about treatment.",[328],[370],"estrogen receptor PET imaging","2026-06-04",{"date":373,"type":33},"2026-06-05",{"date":375,"type":33},"2024-04-05",{"date":377,"type":22},"2028-08-01",{"name":39,"class":40},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":399,"locationsCount":41},"100597524","phase-2-neoadjuvant-intra-tumoral-rp2-and-flot-in-gastroesophageal-adenocarcinoma-100597524","NCT07059611","Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","Phase II Study of Neoadjuvant RP2 in Combination With Preoperative Flot for Patients With Stage II or Higher, Non-metastatic Gastroesophageal Adenocarcinoma","Inclusion Criteria:\n\n* Patients must have histologically confirmed and clinically staged T2 or higher or node positive, non-metastatic esophageal, gastroesophageal junction, or gastric adenocarcinoma.\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.\n* Patents must be deemed a surgical candidate by a thoracic surgeon, surgical oncologist, or surgeon who is qualified to perform the appropriate surgical procedure based on patient's primary tumor site.\n* Patients must have normal organ and bone marrow function, as defined below, less than or equal to 14 days prior to the initiation of study therapy:\n\n  * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmicroliter\n  * Platelets ≥100,000\u002Fmicroliter\n  * Total bilirubin ≤ the institutional upper limit of normal (ULN).\n  * AST and ALT ≤ 2.5 times the institutional ULN\n  * Serum creatinine ≤ 1.5 times the institutional ULN\n  * Hemoglobin ≥ 9 g\u002FdL\n\nExclusion Criteria\n\n* Has received prior chemotherapy, radiation therapy, or immunotherapy (anti-programmed cell death protein-1 (PD-1), anti-programmed death ligand-1 (PD-L1), or anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) for the current malignancy.\n* Per the investigator, has contraindications to receiving chemotherapy with FLOT.\n* Per the sub-investigator (gastroenterologist) responsible for intra-tumoral injections or the investigator, patient has contraindications to repeated upper endoscopy for intra-tumoral injections. These could include medical conditions that would, per the judgment of the sub-investigator or investigator, inappropriately increase the risk of upper endoscopy.\n* Conditions in which anticoagulant therapies cannot be safely stopped in the periprocedural period or patients on warfarin with a target international normalized ratio (INR) ≥ 2.5 that cannot be temporarily reversed to INR ≤ 1.7.\n* Active significant herpetic infections or prior complications of Herpes simplex virus-1 (HSV-1) infection (e.g., herpetic keratitis or encephalitis) or requires intermittent or chronic use of systemic (oral or intravenous \\[IV\\]) antivirals with known antiherpetic activity (e.g., acyclovir). Note: Patients with sporadic cold sores may be enrolled as long as no active cold sores are present at the time of first dose of study treatment.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacille Calmette-Guérin (BCG), and typhoid vaccine. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed, however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Available COVID-19 vaccines do not contain live virus and are allowed.\n* Has a condition requiring systemic treatment with corticosteroids (\\>10mg\u002Fday prednisone equivalents) or other immunosuppressive medications within 14 days of first study treatment administration.\n\n  * Inhaled or topical steroids and adrenal replacement doses ≤ 10mg\u002Fday of prednisone equivalents are permitted.\n* Prior organ transplantation including allogeneic stem-cell transplantation.\n* Has a previous or concurrent malignancy. Exceptions include:\n\n  * Non-melanoma skin cancer, in situ cervical cancer, superficial bladder cancer, or breast cancer in situ OR\n  * Prior malignancy has been completely excised or removed and patient has been continuously disease free for \\> 5-years\n* Has a positive test result for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection with hepatitis B or hepatitis C. Testing will be performed as part of screening on the study.\n\n  * Patients with a known history of hepatitis B or hepatitis C that have been effectively treated (with negative HBsAg and HCV RNA) will be eligible for enrollment on this criterion.\n* Has a known history of human immunodeficiency virus (HIV) with detectable viral load. HIV testing will not be performed as part of screening for the study.\n\n  * Patients with known HIV infection with an undetectable viral load and who are on a stable highly active antiviral regimen per the investigator's assessment will eligible to enroll.\n* Has a psychiatric illness, substance use, or other social conditions that, in the judgment of the investigator, would limit compliance with study requirements.",{"count":387,"type":22},34,[53],"The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.",[391,392,393],"Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","2026-06-03",{"date":373,"type":33},{"date":214,"type":22},{"date":398,"type":22},"2029-11-01",{"name":39,"class":40},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":421},"100388530","phase-2-captemy90-for-grade-23-net-liver-metastases-100388530","NCT04339036","CapTemY90 for Grade 2\u002F3 NET Liver Metastases","UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2\u002F3 Neuroendocrine Tumors","CapTemY90","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of histologic grade 2 or 3 well differentiated neuroendocrine tumor with unresectable liver metastases (primary tumor or other extrahepatic disease may be present)\n* Patients with at least one measurable liver metastases, with size \\> 1cm (RECIST criteria)\n* Patients with liver dominant disease defined as ≥50% tumor body burden confined to the liver\n* Liver tumor burden does not exceed 50% of the liver volume\n* Patent main portal vein\n* At least 4 weeks since last administration of last chemotherapy and \u002For radiotherapy\n* Age \\>18 years.\n* Life expectancy of greater than 6 months.\n* ECOG performance status 0-2.\n* Adequate liver function as measured by: Total bilirubin ≤ 2.0mg\u002Fdl, ALT, AST ≤5 times ULN, albumin ≥2.5g\u002Fdl.\n* Patients must have adequate organ and marrow function as defined below:\n* platelets \\>100,000\u002FmcL (may be corrected by transfusion)\n* serum creatinine \\\u003C 2.0 mg\u002Fdl\n* INR \\\u003C1.6, (may be corrected by transfusion)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Women of child bearing potential and fertile men are required to use effective contraception (negative urine or serum βHCG for women of child-bearing age)\n\nExclusion Criteria:\n\n* Contraindications to capecitibine or temozolomide\n* Contraindicated for both contrast-enhanced MRI and CT\n* Patients previously treated with transarterial embolization (with or without chemotherapy) or with radioembolization (Y-90 microspheres)\n* Contraindication for radioembolization procedures:\n* excessive hepatopulmonary shunt as determined by the investigator\n* inability to deliver Y90 microspheres without risk of non-target embolization of extra-hepatic structures\n* Subjects consenting to the trial who fail their simulation angiography will be removed from the study and replaced.\n* Patients may not be receiving any other investigational agents.\n* Absolute contraindication to intravenous iodinated contrast (Hx of significant previous contrast reaction, not mitigated by appropriate pre-medication).\n* Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal papilla;\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant and lactating women are ineligible",{"count":253,"type":22},[53],"This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.\n\nA Grade 3 arm was added in 2025.",[412,413],"Neuroendocrine Tumor Grade 2","Neuroendocrine Tumors","2026-06-02",{"date":371,"type":33},{"date":417,"type":33},"2021-10-07",{"date":419,"type":22},"2028-07-01",{"name":39,"class":40},4,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":430,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":337},"100513701","assessment-of-a-radiomics-based-computer-aided-diagnosis-tool-for-pulmonary-nodules-100513701","NCT05968898","Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES","Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules","ARCADES","Inclusion Criteria:\n\n1. Male or female, aged 35-89 years\n2. Scheduled to be evaluated at a UPHS PN clinic\n3. Newly discovered solid or part-solid indeterminate PN 8-30mm in maximal diameter on CT imaging within 60 days of index clinic visit\n4. Chest CT imaging meeting the technical requirements for compatibility with Optellum Virtual Nodule Clinic software\n\nExclusion Criteria:\n\n1. Chest CT imaging with discrete mediastinal or hilar lymphadenopathy by CT size criteria (\\>10mm in maximal short-axis diameter on axial CT images)\n2. PNs with popcorn calcification (consistent with benign etiology)\n3. Pure ground-glass subsolid PNs (may be associated with lower risk of clinically significant malignancy)\n4. PN previously seen on CT imaging \\>60 days prior to most recent CT\n5. More than one indeterminate PN 8-30mm in maximal diameter\n6. History of lung cancer\n7. History of active cancer within the previous 5 years\n8. Presence of a thoracic implant that impedes PN visualization","35 Years","89 Years",{"count":433,"type":22},300,[138],"This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.",[437,438],"Lung Cancer","Pulmonary Nodule, Solitary",[440,441,442,443,444],"clinical effectiveness","clinical utility","artificial intelligence","medical decision-making","risk stratification","2026-06-01",{"date":414,"type":33},{"date":448,"type":33},"2024-01-09",{"date":313,"type":22},{"name":39,"class":40},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":41},"100610027","comparing-numbing-techniques-in-mohs-micrographic-surgery-100610027","NCT07222241","Comparing Numbing Techniques in Mohs Micrographic Surgery","Randomized, Double-Blind, Placebo-Controlled Trial of Adjunct Nerve Blocks in Mohs Micrographic Surgery on the Face and Scalp","Inclusion Criteria:\n\n* Age ≥18 years.\n* Scheduled to undergo MMS.\n* Lesions on the face or scalp, defined as the region superior to the mandibular margin anteriorly, superior to the external occipital protuberance posteriorly, and superior to the mastoid processes laterally.\n* Tumor diameter plus anticipated stage 1 MMS margin ≥2 cm in diameter OR any tumor on the ear, lip, nose, or eyelid.\n* Ability to complete patient reported outcome measures in English.\n\nExclusion Criteria:\n\n* Known allergy or contraindication to lidocaine or epinephrine.\n* Chronic opioid use or pre existing pain disorders that may interfere with pain reporting.\n* Presence of scar tissue at the anatomic site of local infiltration or nerve block that may alter anesthetic penetration.\n* Concurrent multi site Mohs procedure.\n* Signs of skin and soft tissue infection at the anatomic site of local infiltration or nerve block.\n* Inability to understand or complete pain and satisfaction assessments.\n* Pregnant or breastfeeding.\n* Use of sedatives or anxiolytics prior to the procedure.",{"count":157,"type":22},[138],"This study seeks to determine whether adjunct regional nerve blocks reduce pain and anxiety in adult patients undergoing Mohs micrographic surgery for face and scalp skin cancers. Participants will be randomized to one of two arms: (1) placebo regional nerve block with sterile normal saline or (2) adjunct regional nerve block with lidocaine. All patients receive local infiltration with lidocaine for complete anesthesia.",[462,463],"Skin Cancer Face","Skin Cancer Scalp",[465,466],"Mohs","Nerve block","2026-05-27",{"date":97,"type":33},{"date":470,"type":33},"2026-01-27",{"date":472,"type":22},"2026-07-31",{"name":39,"class":40},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":41},"100600796","telehealth-collaborative-care-model-cocm-in-lung-cancer-100600796","NCT07102147","Telehealth Collaborative Care Model (CoCM) in Lung Cancer","Increasing Adoption of a Telehealth-Delivered Collaborative Care Program for Patients With Lung Cancer: A Pilot Study","Inclusion Criteria:\n\n* Are aged 18 years or older.\n* Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care.\n* Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services.\n\nExclusion Criteria:\n\n* Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC).\n* Have a significant and\u002For untreated medical and\u002For psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and\u002For homicidal ideation) that make them ineligible for the Penn CoCM program.",{"count":110,"type":22},[138],"The goal of this trial is to compare the impact of two outreach strategies (high touch vs. standard outreach) on a collaborative care program delivered via telehealth to patients with lung cancer.",[485,486,487],"Lung Cancer (Diagnosis)","Anxiety","Depression in Adults",[489,486,490,491],"Lung cancer","Depression","Collaborative care",{"date":493,"type":33},"2026-05-28",{"date":495,"type":33},"2025-08-18",{"date":497,"type":22},"2027-06-30",{"name":39,"class":40},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":506,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":41},"100565159","integrating-telehealth-to-advance-lung-cancer-screening-100565159","NCT06638554","Integrating Telehealth to Advance Lung Cancer Screening","ITALCS","Inclusion criteria:\n\nParticipants will be eligible if:\n\n1. are aged 50 to 80\n2. have a history of tobacco use indicated by either: Documented 20 pack-year or greater smoking history in their electronic health record (EHR); OR Self-report via structured survey\n3. currently smoke or formerly smoked cigarettes\n4. have no documented history of lung cancer\n5. have no documented history of lung cancer screening in the 24 months prior to study enrollment\n6. have completed at least one primary care visit at Penn Medicine in the 3 years prior to study enrollment.\n\nExclusion criteria:\n\nParticipants who do not meet inclusion criteria will not be eligible.","50 Years","80 Years",{"count":509,"type":22},6000,[138],"The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS). It will also learn about the equity of these strategies by conducting non-inferiority analysis by race and sex. The main questions it aims to answer are:\n\n1. Does patient outreach using synchronous and asynchronous telehealth strategies increase completion of SDM visits for LCS?\n2. Is the effectiveness of these telehealth strategies similar by race and sex?\n\nThe study uses a Sequential Multiple Assignment Randomized Trial (SMART) design and includes two stages of interventions. The first stage of intervention includes direct patient outreach with an invitation to schedule either a 1) telehealth SDM visit or 2) telehealth or in-person SDM visit. Participants that do not respond to the first stage interventions receive a text message reminder encouraging SDM visit completion with or without digital care coordination.",[513,514,515],"Early Detection of Cancer","Telemedicine","Decision Making",{"date":97,"type":33},{"date":518,"type":33},"2024-07-09",{"date":497,"type":22},{"name":39,"class":40},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":41},"100551311","phase-2-epcoritamab-car-t-cells-for-large-b-cell-lymphomas-100551311","NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas","Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas","Inclusion Criteria:\n\n* Age \\> 18 years\n* Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally authorized representative (or decision maker when there is not an advanced directive in place) must be willing to provide informed consent on behalf of the patient.\n* Able to comply with the study protocol, in the investigator's judgment\n* ECOG PS of 0 - 2\n* Pathology report confirming eligible diagnosis\n* Documented CD20+ tumor cells on most recent biopsy\n* Patients will have failed to respond to frontline standard of care therapy containing an anthracycline and anti-CD20 antibody\n* Patients will be eligible and consent to be treated with a \"commercially available\" anti-CD19, 4-1BB, CD3zeta CAR-T cell therapy or anti-CD19, CD28, CD3zeta CAR T cell therapy (for example, tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene maraleucel)\n* Patients must have a PET\u002FCT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver)\n* Adequate laboratory studies\n* Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator\n* Ability and willingness to take proper contraceptive precautions\n\nExclusion Criteria:\n\n* Inability or unwillingness of the patient or legally authorized representative (or decision-maker when there is not an advanced directive in place) to provide informed consent.\n* Prior solid organ transplantation\n* Primary central nervous system (CNS) lymphoma or active secondary CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)\u002Fcomputed tomography (CT) scan (brain) or, if clinically indicated, by lumbar puncture.\n* History of autoimmune disease or other diseases resulting in permanent immunosuppression or requiring chronic immunosuppressive therapy (see Exclusion Criteria 5a), with the following exceptions:\n\n  1. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone\n  2. Patients with a history of lymphoma-related immune thrombocytopenic purpura or autoimmune hemolytic anemia in remission may be eligible for this study if approved by the Regulatory Sponsor and Principal Investigator\n  3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n  i. Rash must cover \\\u003C 10% of body surface area ii. Disease is well controlled at baseline and requires only low-potency topical corticosteroid iii. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or corticosteroids (\\> 20 mg\u002Fday prednisone or equivalent for \\> 2 weeks) within the previous 3 months d. rheumatoid arthritis or similar autoimmune\u002Frheumatic conditions\n* Systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). However, the following are permitted:\n\n  1. If receiving glucocorticoid treatment at screening, must be a maximum daily dose of prednisone 10 mg (or equivalent) and a total of no more than 140 mg over the last 14 days prior to the first dose of epcoritamab, unless for disease control.\n  2. Patients who received a single dose of a systemic immunosuppressant medications (e.g., single dose of dexamethasone for nausea or B symptoms) may be enrolled\n  3. The use of inhaled corticosteroids is permitted\n  4. The use of mineralocorticoids for management of orthostatic hypotension is permitted\n  5. The use of physiologic doses of corticosteroids (\\\u003C 20 mg\u002Fday of prednisone or equivalent) for uses such as management of adrenal insufficiency is permitted\n* Known past or current malignancy, other than inclusion diagnoses, except for:\n\n  1. Cervical carcinoma of Stage 1B or less.\n  2. Adequately resected, non-metastatic basal cell or squamous cell skin carcinoma.\n  3. Non-invasive, superficial bladder cancer.\n  4. Prostate cancer with a current PSA level \\\u003C0.1 ng\u002FmL.\n  5. Patients with a malignancy that has been treated with curative intent will also be enrolled if that malignancy is in remission prior to first dose of epcoritamab\n* Known clinically significant cardiovascular disease\n* Patients with the following active infection(s) could have increased risks for toxicity if treated with bispecific antibody therapy, thus patient will be excluded if:\n\n  1. Positive serologic or PCR test results for acute or chronic HBV infection. Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov\u002Fhepatitis\u002Fhbv\u002Fpdfs\u002Fserologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation. Patients with a history of hepatitis B who are negative for HBV by PCR, will not be excluded but will be placed on suppressive antiviral therapy\n  2. Acute or chronic HCV infection. Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation. Patients with a history of hepatitis C who have been adequately treated (negative PCR) will not be excluded.\n  3. Positive serologic or RT-PCR test results for HIV infection.\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks of enrollment. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.\n* Clinically significant pulmonary disease (e.g., bronchospasm and\u002For obstructive pulmonary disease) that requires chronic oxygen or corticosteroid use \\> 20 mg mg\u002Fday prednisone or equivalent\n* Uncontrolled seizure disorder\n* Exposure to live or live attenuated vaccine within 4 weeks prior to signing ICF\n* Pregnancy or breast feeding\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results",{"count":529,"type":22},31,[53],"This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.",[533,534,535,536,537],"Lymphoma, Non-Hodgkin","Relapsed Diffuse Large B Cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma","Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","2026-05-22",{"date":467,"type":33},{"date":541,"type":33},"2024-09-24",{"date":543,"type":22},"2027-12",{"name":39,"class":40},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":173},"100430794","phase-2-car-t-followed-by-bispecific-antibodies-100430794","NCT04889716","CAR-T Followed by Bispecific Antibodies","Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas","Inclusion Criteria:\n\n* Life expectancy of at least 12 weeks\n* History of relapsed or refractory large B-cell lymphoma (including transformed follicular lymphoma, and follicular lymphoma Grade 3B) who have relapsed after or failed to respond to at least one prior standard systemic treatment regimen that contains an anthracycline and at least one containing an anti-CD20-directed therapy and for whom there is no available therapy expected to improve survival (e.g., standard chemotherapy, autologous or allogeneic stem cell transplant).\n* PET\u002FCT scan (preferred), diagnostic CT scan, or MRI prior to CAR-T cell therapy, with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver); this imaging must have been obtained within 56 days of receiving CAR T cell therapy.\n* PET\u002FCT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver); this imaging documenting measurable disease must be obtained at least day +28 after CAR T cell infusion and prior to cycle 1 day 1.\n* Be at least 30 days after CAR T-cell infusion at time of study enrollment.\n* Adequate laboratory studies,\n* Ability and willingness to take proper contraceptive precautions\n\nExclusion Criteria:\n\n* Had \\> Grade 3 cytokine release syndrome (CRS) by ASTCT criteria after CAR-T therapy or who have unresolved CRS after CAR-T therapy\n* Had ≥ grade 2 neurologic toxicity by ASTCT criteria after CAR-T therapy or who have active neurologic toxicity after CAR-T therapy\n* Inability to comply with protocol-mandated hospitalization and activities restrictions in the investigators' decision\n* Pregnant or lactating, or intending to become pregnant during the study or within 3 months after the last dose of bispecific antibody or 18 months of obinutuzumab, whichever comes later\n* Prior solid organ transplantation\n* Active systemic autoimmune disease or other disease requiring chronic immunosuppressive therapy\n* History of confirmed progressive multifocal leukoencephalopathy (PML)\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)\n* History of other malignancy that could affect compliance with the protocol or interpretation of results\n* Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina)\n* Significant active pulmonary disease (e.g., bronchospasm and\u002For obstructive pulmonary disease) requiring oxygen or corticosteroid use.\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to first mosunetuzumab or glofitamab administration. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.\n* Recent major surgery within 4 weeks prior to first mosunetuzumab or glofitamab administration\n* Active or chronic infection(s) would have increased risks for toxicity if treated with bispecific antibody therapy, thus will be excluded.\n* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study\n* Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment \\\u003C 20 mg\u002Fday prednisone or equivalent within 2 weeks prior to first dose of bispecific antibody\n* History of drug or alcohol abuse within 12 months prior to screening in the investigator's judgment\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's and\u002For Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results",{"count":182,"type":22},[53],"The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).",[556,557],"Large B-cell Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma","2026-05-21",{"date":560,"type":33},"2026-05-26",{"date":562,"type":33},"2021-11-05",{"date":564,"type":22},"2028-12-31",{"name":39,"class":40},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":41},"100402714","phase-2-abemaciclib-or-abemaciclib-and-hydroxychloroquine-to-target-minimal-residual-disease-in-breast-cancer-100402714","NCT04523857","ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (\"ABBY\")","ABBY","Inclusion Criteria:\n\n* Histologically-confirmed, primary, invasive breast cancer diagnosed within 5 years of entry into the companion DTC screening protocol UPCC 28115\n* Qualifying risk status, at diagnosis utilizing receptor testing by ASCO\u002FCAP guidelines, meting at least one of the following:\n\n  (i) Lymph node involvement\n\n  a. Pathologically-confirmed positive axillary lymph nodes, regardless of receptors, or (b) Evidence of lymph node involvement by preoperative imaging AND fibrosis and\u002For treatment effect in lymph nodes after neoadjuvant therapy, regardless of receptor status (ii) Primary tumor that is ER\u002FPR\u002FHer2 negative: estrogen receptor (ER) \\\u003C 10%, progesterone receptor (PR) \\\u003C 10% and negative for Her2-overexpression by ASCO-CAP guidelines, regardless of lymph nodes status (iii) Primary tumor that is ER+\u002FHer2 negative\u002FLymph node negative with Breast Cancer Recurrence Score of \\>\u002F= 25 per the Genomic Health Oncotype DX breast cancer test and\u002For high risk MammaPrint (iv) Evidence of residual disease in the breast on pathologic assessment after neoadjuvant chemotherapy\n* Patients must have completed all primary therapy (definitive surgery, (neo)adjuvant chemotherapy adjuvant radiation and\u002For Her2-directed therapy) for the index malignancy at least 4 weeks prior to study entry. Prior treatment-related toxicity must be resolved or improving to Grade 1 with the exception of alopecia, Grade 2 endocrine disorders (e.g. adrenal insufficiency or thyroid disorders from prior immunotherapy) controlled on stable replacement therapy for \\> 1 year, and up to Grade 3 peripheral neuropathy, prior to study enrollment. Concurrent receipt of adjuvant endocrine and bone modifying agents is allowed per standard of care guidelines. Tamoxifen is not allowed due to drug-drug interactions with HCQ.\n* Bone marrow aspirate obtained via research trial UPCC 28115 after completion of therapy (except endocrine therapy) demonstrates detectable DTCs (via IHC)\n* No evidence of recurrent local or distant breast cancer by physical examination, blood tests (CBC, LFTs, Alk Phos), or imaging. Assessment for overt metastatic disease by radiologic testing per institutional guidelines (CT Chest, Abdomen and Pelvis, bone scan, MRI and\u002For PET\u002FCT) will only be done in patients with DTCs detected on bone marrow aspirate who are being screened for this trial.\n* Age \\>\u002F= 18 years\n* ECOG performance status =\u002F\\\u003C 2\n* Ability to swallow oral medications\n* No contraindications to the study medications or uncontrolled medical illness.\n* Adequate bone marrow function as shown by: ANC \\>\u002F= 1.5 x 10\\^9\u002FL, Platelets \\>\u002F= 100 x 10\\^9\u002FL, Hb \\>9 g\u002FdL\n* Adequate liver function as shown by: Serum bilirubin \\\u003C\u002F= 1.5 x ULN, ALT and AST \\\u003C\u002F= 3.0 x ULN, and INR \\\u003C\u002F=1.5\n* Adequate renal function: serum creatinine \\\u003C\u002F= 1.5 x ULN\n* Adequate muscle function: creatinine phosphokinase (CPK) \\\u003C\u002F= 2.5 x ULN\n* Anticoagulation is allowed if target INR =\u002F\\\u003C 1.5 on a stable dose of warfarin or on a stable dose of anticoagulant for \\>2 weeks at time of randomization\n* Ability to provide informed consent\n\nExclusion Criteria\n\n* Concurrent enrollment on another investigational therapy\n* Patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization (or treatment assignment), or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study.\n* Prior treatment with abemaciclib is not allowed. (Patients may have received prior CDK4\u002F6 inhibitor therapy with an agent other than abemaciclib. Patients must have discontinued CDK4\u002F6 inhibitor at least 6 months prior to screening.)\n* Known hypersensitivity to hydroxychloroquine or any of its derivatives\n* Prior hydroxychloroquine exposure for a duration of \\> 1 month since the completion of the patient's primary therapy (definitive surgery, (neo)adjuvant chemotherapy, adjuvant radiation, and\u002For Her2-directed therapy) for the index malignancy.\n* Patients with hormone-receptor positive breast cancer may not be receiving tamoxifen due to drug-drug interactions with hydroxychloroquine\n* Patients who have initiated bone modifying agents within 3 months prior to the start of study treatment\n* Patients who have had major surgery within 14 days prior to randomization (or treatment assignment)\n* Patients who have any severe and\u002For uncontrolled medical conditions or other conditions that could affect their participation in the study\n* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of Abema",{"count":575,"type":22},44,[53],"This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cells in bone marrow can reduce their number or eliminate them. Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are approved by the FDA",[141],{"date":560,"type":33},{"date":581,"type":33},"2021-11-01",{"date":147,"type":22},{"name":39,"class":40},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":41},"100561138","phase-1-adjuvant-concurrent-immunotherapy-and-radiotherapy-for-the-treatment-of-bladder-cancer-100561138","NCT06586255","Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer","Phase I Safety Trial of Concurrent Adjuvant Immunotherapy and Radiation Therapy for the Treatment of Urothelial Bladder Cancer","Inclusion Criteria:\n\n* Pure or mixed variant urothelial carcinoma\n\n  o Allowable mixed variant subtypes include:\n  * squamous differentiation\n  * glandular differentiation\n  * nested pattern\n  * microcystic\n  * micropapillary\n  * lymphoepthelioma-like\n  * plasmacytoid and lymphoma-like\n  * sarcomatoid\u002Fcarcinosarcoma\n  * giant cell\n  * trophoblastic differentiation\n  * clear cell\n  * lipid cell\n  * undifferentiated\n* Radical cystectomy and pelvic lymph node dissection within the prior 48 weeks\n* Pathologic T3 or higher stage disease, any N, M0 (AJCC, 7th Ed., Appendix C)\n* Receiving adjuvant checkpoint inhibitor therapy\n* No clinical evidence of residual or recurrent disease based on the following minimum diagnostic work-up within 3 months of a patient's consent to participate.\n\n  * History and physical examination\n  * Chest imaging by x-ray (PA and lateral views), CT scan (with or without IV contrast) or as part of a FDG PET-CT;\n  * Axial abdominal and pelvic imaging by MRI (preferably with gadolinium), CT scan (with or without IV contrast) or as part of a FDG PET-CT;\n  * Patients with microscopically involved (positive) surgical margins, but no grossly evident residual disease by imaging or physical exam are eligible.\n* The patient is a candidate for definitive external beam radiotherapy;\n\n  * No prior radiotherapy to the region of study;\n  * No inflammatory bowel disease, active collagen vascular or connective tissue disorders, and no other medical or social contraindications to radiotherapy, as determined by a participating radiation oncologist;\n* Age greater than or equal to 18 years\n* ECOG performance status: 0-2\n* Concurrent non-investigational medications will be permitted\n* In addition to diagnostic staging scan, patient will be considered eligible only if he\u002Fshe has a CT simulation scan that does not show any evidence of recurrent disease\n* Informed consent: Patients must have the ability to understand and be willing to sign the study-specific informed consent indicating their understanding of the investigational nature and the risks of this study before any of the protocol related studies are performed (this does not include routine laboratory testing or imaging studies required to establish study eligibility)\n\nExclusion Criteria:\n\n* Urinary diversion with an orthotopic neobladder\n* History of inflammatory bowel disease\n* Prior partial or complete small bowel obstruction either before or after radical cystectomy\n* Prior radiotherapy to the pelvis;\n\n  o Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant's prior and current course of radiation therapy, radiotherapy was completed more than four weeks from enrolling in this study.\n* Planned concurrent chemotherapy or other investigational drug to be given with radiation treatments\n\n  o Prior chemotherapy or investigational drug for bladder cancer or a different cancer is allowed, provided that:\n  * The therapy was completed more than two weeks prior to the start of adjuvant pelvic radiation\n  * The participant has recovered to Grade ≤1 toxicity from agents previously administered, excluding toxicities that would not be expected to impact eligibility for radiation therapy including but not limited to neuropathy, alopecia and hearing loss.\n* Subtotal surgical resection with clinically evident residual disease by physical exam or axial imaging.\n* Prior or concurrent second invasive malignancy that, in the judgment of the investigator, may affect interpretation of the results.\n* Known severe, active co-morbidity, defined as follows:\n\n  o Any clinically significant unrelated systemic illness, medical condition, or other factor, which at the discretion of the Principal Investigators, would interfere in the safe and timely completion of study procedures, compromise the patient's ability to tolerate the protocol therapy, or is likely to interfere with the study procedures or results.\n* Patients who experienced Grade 3+ GI toxicity due to surgery or nivolumab prior to enrollment in the trial",{"count":21,"type":22},[52],"The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.",[595,596],"Urothelial Carcinoma Bladder","Bladder Cancer","2026-05-12",{"date":599,"type":33},"2026-05-14",{"date":601,"type":33},"2025-04-29",{"date":603,"type":22},"2027-04",{"name":39,"class":40},""]